WebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. Web26 mrt. 2024 · Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins …
Ikena Oncology - Atlas Venture
WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel … psychology classical conditioning examples
Ikena Oncology Biomarker-Driven Cancer Therapeutics
Web7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known. WebPatient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies … host vmotion